CD79A Gene Agammaglobulinemia type 3 autosomal recessive Genetic Test sale cost 4400 AED
MDM2 Gene Accelerated tumor formation susceptibility to Genetic Test sale cost 4400 AED MDM2 Gene Accelerated tumor formation susceptibility to Genetic Test 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
ACTN1 Gene Bleeding Disorder Platelet-Type 15 Genetic Test sale cost 4400 AED ACTN1 Gene Bleeding Disorder Platelet-Type 15 Genetic Test 5,600 د.إ Original price was: 5,600 د.إ.4,400 د.إCurrent price is: 4,400 د.إ.
Sale!

CD79A Gene Agammaglobulinemia type 3 autosomal recessive Genetic Test

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The CD79A gene plays a crucial role in the immune system’s ability to fight infections. Mutations in this gene can lead to a condition known as Agammaglobulinemia type 3, an autosomal recessive disorder. This rare genetic condition is characterized by an almost complete lack of immunoglobulins or antibodies in the blood, making individuals highly susceptible to infections.

To diagnose this condition, a genetic test focusing on the CD79A gene can be conducted. This test is crucial for identifying mutations in the CD79A gene that are responsible for Agammaglobulinemia type 3. Early diagnosis through genetic testing allows for timely intervention and management of the condition, helping to prevent severe infections and improve quality of life for affected individuals.

In the United Arab Emirates, DNA Labs UAE offers this specialized genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology to provide accurate and reliable genetic testing services, ensuring that individuals and families receive the crucial information needed for managing Agammaglobulinemia type 3 and related conditions.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive Genetic Test

Test Details

CD79A gene agammaglobulinemia type 3 is a rare genetic disorder characterized by a deficiency of B cells, which are responsible for producing antibodies. This condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated CD79A gene, one from each parent, to develop the disorder.

NGS (Next-Generation Sequencing) genetic testing is a diagnostic tool used to identify mutations in genes associated with various genetic disorders, including CD79A gene agammaglobulinemia type 3. This type of testing involves sequencing the DNA of an individual to identify any genetic variants or mutations that may be present. By identifying mutations in the CD79A gene, NGS genetic testing can confirm a diagnosis of agammaglobulinemia type 3 and help guide treatment decisions. Additionally, it can also be used for carrier testing in individuals with a family history of the disorder to determine their risk of passing the mutated gene to their children.

It is important to note that NGS genetic testing should be performed by a qualified healthcare professional or genetic counselor who can interpret the results and provide appropriate genetic counseling and guidance.

Test Name: CD79A Gene Agammaglobulinemia Type 3 Autosomal Recessive Genetic Test

Components:

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Hematology
  • Doctor: Hematologist
  • Test Department: Genetics

Pre Test Information:

Clinical History of Patient who is going for CD79A Gene Agammaglobulinemia type 3, autosomal recessive NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CD79A Gene Agammaglobulinemia type 3, autosomal recessive NGS Genetic DNA Test gene CD79A.

Test Details:

CD79A gene agammaglobulinemia type 3 is a rare genetic disorder characterized by a deficiency of B cells, which are responsible for producing antibodies. This condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated CD79A gene, one from each parent, to develop the disorder. NGS (Next-Generation Sequencing) genetic testing is a diagnostic tool used to identify mutations in genes associated with various genetic disorders, including CD79A gene agammaglobulinemia type 3. This type of testing involves sequencing the DNA of an individual to identify any genetic variants or mutations that may be present. By identifying mutations in the CD79A gene, NGS genetic testing can confirm a diagnosis of agammaglobulinemia type 3 and help guide treatment decisions. Additionally, it can also be used for carrier testing in individuals with a family history of the disorder to determine their risk of passing the mutated gene to their children. It is important to note that NGS genetic testing should be performed by a qualified healthcare professional or genetic counselor who can interpret the results and provide appropriate genetic counseling and guidance.

Test Name CD79A Gene Agammaglobulinemia type 3 autosomal recessive Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Hematology
Doctor Hematologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CD79A Gene Agammaglobulinemia type 3, autosomal recessive NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CD79A Gene Agammaglobulinemia type 3, autosomal recessive NGS Genetic DNA Test gene CD79A
Test Details

CD79A gene agammaglobulinemia type 3 is a rare genetic disorder characterized by a deficiency of B cells, which are responsible for producing antibodies. This condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated CD79A gene, one from each parent, to develop the disorder.

NGS (Next-Generation Sequencing) genetic testing is a diagnostic tool used to identify mutations in genes associated with various genetic disorders, including CD79A gene agammaglobulinemia type 3. This type of testing involves sequencing the DNA of an individual to identify any genetic variants or mutations that may be present.

By identifying mutations in the CD79A gene, NGS genetic testing can confirm a diagnosis of agammaglobulinemia type 3 and help guide treatment decisions. Additionally, it can also be used for carrier testing in individuals with a family history of the disorder to determine their risk of passing the mutated gene to their children.

It is important to note that NGS genetic testing should be performed by a qualified healthcare professional or genetic counselor who can interpret the results and provide appropriate genetic counseling and guidance.

SKU: TEST-3856 Category:

Related products